Therefore, it is an urgent to find new biomarkers with predictive value for melanoma or other solid tumors that are ineffective or resistance in the treatment of PD-1 or PD-L1 inhibitors, and ultimately improve the efficacy of PD-1 or PD-L1 inhibitors. The gene discussed is PDCD1; the disease is melanoma.